MX338195B - Preparaciones de anticuerpos. - Google Patents

Preparaciones de anticuerpos.

Info

Publication number
MX338195B
MX338195B MX2012012263A MX2012012263A MX338195B MX 338195 B MX338195 B MX 338195B MX 2012012263 A MX2012012263 A MX 2012012263A MX 2012012263 A MX2012012263 A MX 2012012263A MX 338195 B MX338195 B MX 338195B
Authority
MX
Mexico
Prior art keywords
antibody preparation
preparation
antibody preparations
antibodies
antibody
Prior art date
Application number
MX2012012263A
Other languages
English (en)
Other versions
MX2012012263A (es
Inventor
Matthias Germer
Wolfgang Möller
Dieter Rudnick
Oliver Maneg
Michael Rodemer
Veit Braun
Original Assignee
Biotest Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42270688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX338195(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotest Ag filed Critical Biotest Ag
Publication of MX2012012263A publication Critical patent/MX2012012263A/es
Publication of MX338195B publication Critical patent/MX338195B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/125—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Chlamydiales (O)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una preparación de anticuerpos adecuada para administración intravenosa en humanos, que comprende IgG, IgA y al menos anticuerpos IgM al 5% en peso de la cantidad total de anticuerpos, en donde la preparación se elabora a partir de plasma humano, en donde la preparación de anticuerpos tiene actividad de activación de complemento específica y en donde en un ensayo in vitro con suero humano adecuado para determinar la capacidad de la preparación de anticuerpos para activar complemento en forma no específica la preparación de anticuerpos sustancialmente no genera C5a y/o sustancialmente no genera C3a. Además se proporcionan usos médicos de la preparación de anticuerpo.
MX2012012263A 2010-04-22 2011-04-21 Preparaciones de anticuerpos. MX338195B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1006753.6A GB201006753D0 (en) 2010-04-22 2010-04-22 Process for preparing an immunolobulin composition
PCT/EP2011/056487 WO2011131787A2 (en) 2010-04-22 2011-04-21 Antibody preparations

Publications (2)

Publication Number Publication Date
MX2012012263A MX2012012263A (es) 2012-11-23
MX338195B true MX338195B (es) 2016-04-06

Family

ID=42270688

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012012263A MX338195B (es) 2010-04-22 2011-04-21 Preparaciones de anticuerpos.
MX2012012262A MX337060B (es) 2010-04-22 2011-04-21 Proceso para preparar una composicion de inmunoglobulina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012012262A MX337060B (es) 2010-04-22 2011-04-21 Proceso para preparar una composicion de inmunoglobulina.

Country Status (20)

Country Link
US (6) US8900806B2 (es)
EP (2) EP2560682B2 (es)
JP (4) JP6283517B2 (es)
KR (2) KR101860459B1 (es)
CN (3) CN102939107B (es)
AU (2) AU2011244240B2 (es)
BR (2) BR112012026934A2 (es)
CA (2) CA2796263C (es)
CO (2) CO6640239A2 (es)
ES (2) ES2553385T3 (es)
GB (1) GB201006753D0 (es)
HK (2) HK1177600A1 (es)
HU (2) HUE028581T2 (es)
IL (2) IL222373A (es)
MX (2) MX338195B (es)
PL (2) PL2560682T5 (es)
RU (4) RU2749732C2 (es)
SG (2) SG184844A1 (es)
WO (2) WO2011131787A2 (es)
ZA (2) ZA201208540B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
FR2959821B1 (fr) * 2010-05-05 2012-07-06 Lab Francais Du Fractionnement Procede de mesure de l'activation du complement par des igg
FR2974301B1 (fr) 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
FR2977893B1 (fr) * 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
BR112014022240A2 (pt) 2012-03-09 2017-08-01 Csl Behring Ag composições compreendendo imunoglobulinas semelhantes à secretoras
EP2636681A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Process for enriching IgA
EP2636684A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
KR20150115639A (ko) * 2014-04-04 2015-10-14 전숙영 치료용 면역글로불린 제제 제조에 사용되는 산성 완충액, 이를 이용한 치료용 면역글로불린 제제 제조방법 및 이 제조방법으로 제조된 치료용 면역글로불린 제제
US20170210793A1 (en) * 2014-07-15 2017-07-27 The Regents Of The University Of California Novel Treatment for Polycystic Kidney Disease
WO2017027861A1 (en) 2015-08-13 2017-02-16 Amgen Inc. Charged depth filtration of antigen-binding proteins
PL3429622T3 (pl) 2016-03-14 2021-11-02 Biotest Ag Leczenie ciężkiego pozaszpitalnego zapalenia płuc
EP3275897A1 (en) 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
RU2660584C1 (ru) * 2017-06-06 2018-07-06 Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" Способ определения FC-функции препаратов иммуноглобулина человека
MX2020004921A (es) * 2017-11-29 2020-08-27 Hoffmann La Roche Ensayo de anticuerpo antifarmaco con supresion de interferencia del objetivo.
EP3747903A1 (en) 2019-06-07 2020-12-09 Biotest AG Method and kit for testing potency of immunoglobulin compositions
KR20220166819A (ko) * 2020-04-10 2022-12-19 바누디스 게엠베하 예방 및 치료에서의 천연 항체
EP4161572A1 (en) * 2020-06-03 2023-04-12 Grifols Worldwide Operations Limited Hyperimmune igg and/or igm compositions and method for preparing thereof and method for obtaining hyperimmune human plasma from a donor
TW202216735A (zh) * 2020-07-10 2022-05-01 愛爾蘭商格里佛全球營運有限公司 製備包含人血漿來源的免疫球蛋白ｍ之組合物的方法及儲存穩定的液體組合物
CN111944043B (zh) * 2020-09-01 2023-05-09 华兰生物工程重庆有限公司 一种从血浆废弃物中提取IgM的方法
EP4193155A1 (en) 2020-11-19 2023-06-14 Biotest AG Method and kit for testing immunomodulatory potency of immunoglobulin compositions, e.g., for treatment of covid-19
AU2022317368A1 (en) 2021-07-29 2024-02-22 Csl Behring Ag Method of purifying immunoglobulin g and uses thereof
WO2024200757A1 (en) 2023-03-29 2024-10-03 Csl Behring Ag Methods of identifying immunoglobulin associated with adverse reactions

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US136556A (en) 1873-03-04 Improvements in button-fastenings
DE2901822A1 (de) 1979-01-18 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt
US4371520A (en) * 1981-10-28 1983-02-01 The Green Cross Corporation Process for preparing immunoglobulin suitable for intravenous injection
DE3310150A1 (de) * 1983-03-21 1984-09-27 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Verfahren zur herstellung einer nebenwirkungsfreien igg-immunglobulinloesung fuer die intravenoese applikation
IL90281A (en) 1988-06-06 1994-10-07 Miles Inc Preparations containing MGI antibodies
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
US4939176A (en) † 1988-12-20 1990-07-03 Miles Inc. Viral inactivation process
DE3927111C3 (de) * 1989-08-17 1994-09-01 Biotest Pharma Gmbh Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate
DE3927112C1 (es) * 1989-08-17 1990-10-25 Biotest Pharma Gmbh, 6072 Dreieich, De
US5256771A (en) * 1990-04-03 1993-10-26 Miles Inc. Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation
US5367054A (en) * 1993-04-12 1994-11-22 Stolle Research & Development Corp. Large-scale purification of egg immunoglobulin
ATE367830T1 (de) 1995-07-14 2007-08-15 Caf Dcf Cvba Scrl Vorrichtung zur inaktivierung von viralen kontaminationen in blutprodukten
DE59509979D1 (de) 1995-09-22 2002-02-07 Zlb Bioplasma Ag Bern Verfahren zur Gewinnung von Immunglobulinen aus Fraktionen, die bei der Fraktionierung von menschlichem Blutplasma entstehen
EP0835880A1 (de) * 1996-10-14 1998-04-15 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Verfahren zur Herstellung eines IgM Präparates für die intravenöse Applikation
JP3987599B2 (ja) * 1996-12-05 2007-10-10 日本製薬株式会社 筋ジストロフィー治療剤
JPH10167894A (ja) * 1996-12-11 1998-06-23 Mitsubishi Gas Chem Co Inc ビスマス置換希土類鉄ガーネット単結晶膜の製造法
US6955917B2 (en) * 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
AU753468B2 (en) 1998-06-09 2002-10-17 Csl Behring Ag Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
RU2178309C2 (ru) * 2000-01-12 2002-01-20 Российский научно-исследовательский институт геронтологии Антитимоцитарный глобулин для внутривенного введения и способ его получения
RU2192279C2 (ru) * 2000-09-07 2002-11-10 Нижегородское государственное предприятие по производству бактерийных препаратов Способ получения иммуноглобулинового препарата
DK1337280T3 (da) † 2000-11-13 2013-12-02 Bayer Ip Gmbh Fremgangsmåde til inaktivering af mikroorganismer i en fluid ved anvendelse af ultraviolet stråling
FR2824568B1 (fr) † 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
US7727974B2 (en) 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
JP4191037B2 (ja) * 2001-11-02 2008-12-03 日本テクノ株式会社 滅菌用振動攪拌装置並びに振動攪拌装置を用いる滅菌装置及び滅菌方法
RU2255766C2 (ru) * 2003-03-05 2005-07-10 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габрического Министерства здравоохранения Российской Федерации" Способ получения иммуноглобулинового препарата для профилактики и терапии бактериальных и вирусных инфекций, иммуноглобулиновый препарат для профилактики и терапии бактериальных и вирусных инфекций (варианты) и суппозитории на основе иммуноглобулинового препарата
EP1615946B1 (en) 2003-03-26 2020-05-06 Sudhir Paul Proteolytic and covalent antibodies
DK1678208T3 (da) † 2003-10-27 2013-07-08 Wyeth Llc Fjernelse af aggregater med høj molekylvægt under anvendelse af hydroxyapatitchromatografi
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
MXPA06008435A (es) 2004-01-30 2007-05-23 Suomen Punainen Risti Veripalvelu Proceso de manufactura de una inmunoglobulina libre de virus.
UA87836C2 (ru) 2004-02-27 2009-08-25 Октафарма Аг Способ получения очищенных, безопасных с вирусологической точки зрения препаратов антител
PT1830881E (pt) 2004-12-10 2010-08-30 Novimmune Sa Terapias de combinação visando múltiplos receptores do tipo toll e a sua utilização
WO2006064373A2 (en) † 2004-12-16 2006-06-22 Genzyme Polyclonals S.A.S. Methods of purifying immunologlobulins
KR101157174B1 (ko) † 2005-11-24 2012-06-20 삼성전자주식회사 세포 또는 바이러스의 신속한 파괴 방법 및 장치
DE102005062634A1 (de) 2005-12-23 2007-06-28 Blutspendedienst der Landesverbände des Deutschen Roten Kreuzes Niedersachsen, Sachsen-Anhalt, Thüringen, Oldenburg und Bremen gGmbH Verfahren zur Inaktivierung von Pathogenen in Spenderblut, Blutplasma oder Erythrozytenkonzentraten in flexiblen Behältnissen unter Bewegung
FR2899112B1 (fr) † 2006-03-31 2010-09-03 Lab Francais Du Fractionnement Concentre d'immunoglobulines et de fragments f (ab)'2 et/ou fab specifiques d'un arbovirus en tant que medicament.
FR2899111B1 (fr) 2006-03-31 2010-09-03 Lab Francais Du Fractionnement Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament.
US8354076B2 (en) † 2006-10-02 2013-01-15 Palo Alto Research Center Incorporated Fluid stirring mechanism
EP1950225A1 (de) † 2007-01-25 2008-07-30 Octapharma AG Verfahren zur Steigerung von Proteinausbeuten
WO2009140236A2 (en) † 2008-05-12 2009-11-19 Strox Biopharmaceuticals, Llc Staphylococcus aureus-specific antibody preparations
RU2457863C2 (ru) * 2008-08-05 2012-08-10 Виктор Владимирович Чалов Композиция, обладающая противовирусным и антимикробным действием, содержащая консорциум иммуноглобулинов
RU2457861C2 (ru) * 2008-08-05 2012-08-10 Виктор Владимирович Чалов Композиция, обладающая противовирусным и антимикробным действием, содержащая консорциум иммуноглобулинов
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
NZ591514A (en) † 2011-03-03 2013-11-29 Kode Biotech Ltd Assay method

Also Published As

Publication number Publication date
PL2560691T3 (pl) 2016-04-29
HK1180601A1 (zh) 2013-10-25
RU2749732C2 (ru) 2021-06-16
RU2612899C2 (ru) 2017-03-13
AU2011244240B2 (en) 2014-12-04
HK1177600A1 (zh) 2013-08-23
RU2617532C2 (ru) 2017-04-25
SG184843A1 (en) 2012-11-29
EP2560691B1 (en) 2015-11-04
CO6640239A2 (es) 2013-03-22
WO2011131787A3 (en) 2011-12-22
CN102939111A (zh) 2013-02-20
CA2796263A1 (en) 2011-10-27
IL222374A (en) 2017-04-30
EP2560682B2 (en) 2024-01-17
ES2551605T3 (es) 2015-11-20
US10954290B2 (en) 2021-03-23
EP2560682B1 (en) 2015-10-21
US20130045199A1 (en) 2013-02-21
KR101860459B1 (ko) 2018-05-23
CN102939107A (zh) 2013-02-20
WO2011131786A3 (en) 2011-12-22
RU2012149743A (ru) 2014-05-27
BR112012026934A2 (pt) 2015-09-22
WO2011131787A2 (en) 2011-10-27
BR112012026937A2 (pt) 2016-07-12
US9518110B2 (en) 2016-12-13
RU2017111820A3 (es) 2020-07-20
CA2796263C (en) 2019-05-14
PL2560682T5 (pl) 2024-04-29
CN107080842A (zh) 2017-08-22
AU2011244241B2 (en) 2014-12-04
KR20130094718A (ko) 2013-08-26
US10059759B2 (en) 2018-08-28
ZA201208541B (en) 2015-06-24
JP6118248B2 (ja) 2017-04-19
MX2012012263A (es) 2012-11-23
RU2765738C2 (ru) 2022-02-02
JP6612182B2 (ja) 2019-11-27
ZA201208540B (en) 2015-06-24
CA2796409A1 (en) 2011-10-27
JP6283517B2 (ja) 2018-02-21
SG184844A1 (en) 2012-11-29
HUE028581T2 (en) 2016-12-28
RU2017111820A (ru) 2019-01-24
JP2013531630A (ja) 2013-08-08
PL2560682T3 (pl) 2016-04-29
US20210179694A1 (en) 2021-06-17
JP2016222674A (ja) 2016-12-28
JP6612186B2 (ja) 2019-11-27
HUE025853T2 (en) 2016-05-30
IL222373A (en) 2016-02-29
RU2016140455A (ru) 2018-12-17
US20150064170A1 (en) 2015-03-05
AU2011244240A1 (en) 2012-12-06
US20180319871A1 (en) 2018-11-08
US11780909B2 (en) 2023-10-10
US20130052208A1 (en) 2013-02-28
IL222373A0 (en) 2012-12-31
IL222374A0 (en) 2012-12-31
EP2560691A2 (en) 2013-02-27
RU2012149741A (ru) 2014-05-27
MX337060B (es) 2016-02-09
RU2016140455A3 (es) 2020-04-02
CO6640238A2 (es) 2013-03-22
US8900806B2 (en) 2014-12-02
US20170058020A1 (en) 2017-03-02
JP2013530950A (ja) 2013-08-01
US9243056B2 (en) 2016-01-26
CN102939107B (zh) 2016-12-21
ES2553385T3 (es) 2015-12-09
EP2560682A2 (en) 2013-02-27
KR101872747B1 (ko) 2018-06-29
MX2012012262A (es) 2012-11-23
GB201006753D0 (en) 2010-06-09
JP2016196477A (ja) 2016-11-24
KR20130060199A (ko) 2013-06-07
ES2551605T5 (es) 2024-06-27
WO2011131786A2 (en) 2011-10-27
CN102939111B (zh) 2014-10-29
AU2011244241A1 (en) 2012-12-06

Similar Documents

Publication Publication Date Title
MX338195B (es) Preparaciones de anticuerpos.
Lelis et al. Myeloid-derived suppressor cells modulate B-cell responses
Zhang et al. Anti-West Nile virus activity of in vitro expanded human primary natural killer cells
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
MX348581B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
PH12017501075B1 (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
GB201201314D0 (en) Composition
WO2007115049A3 (en) Humanized monoclonal antibodies to hepatocyte growth factor
WO2013088148A3 (en) Method of treatment employing therapeutic t cell product from mobilised donors
WO2007097934A3 (en) Methods and compositions for using erythrocytes as carriers for delivery of drugs
UA112747C2 (uk) Лікарський засіб і спосіб профілактики інфікування віл, профілактики і лікування захворювань, що викликаються віл або асоційовані з віл, у тому числі сніду
UA111825C2 (uk) Стабілізований препарат, що містить антитіло проти ngf
Miroux et al. Inhibitory effects of cyclosporine on human regulatory T cells in vitro
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
Camisaschi et al. Targeting immune regulatory networks to counteract immune suppression in cancer
NZ612175A (en) Anti ccr4 antibodies and uses thereof
WO2012010966A3 (en) A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
Kim et al. Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells
MX2014001626A (es) Preservacion asistida con vacio de productos biologicos, en particular de vacunas.
CA2818951A1 (en) Human lactoferrin derived peptide for use as an antigen masking agent
JP2013523886A5 (es)
WO2011130249A3 (en) Methods and compositions for inhibition of treg cells
AU2012305807A8 (en) Dengue-virus serotype neutralizing antibodies
MX2013002718A (es) Composiciones de anticuerpo anti-vegfr-3.
Mifsud et al. Generation of adaptive immune responses following influenza virus challenge is not compromised by pre-treatment with the TLR-2 agonist Pam2Cys

Legal Events

Date Code Title Description
FG Grant or registration